Michael J. Tomsicek
2018 - ABIOMED
In 2018, Michael J. Tomsicek earned a total compensation of $1.3M as Vice President, Chief Financial Officer and Treasurer at ABIOMED, a 41% decrease compared to previous year.
Compensation breakdown
Option Awards | $294,995 |
---|---|
Salary | $378,525 |
Stock Awards | $605,295 |
Total | $1,278,815 |
Tomsicek received $605.3K in stock awards, accounting for 47% of the total pay in 2018.
Tomsicek also received $295K in option awards and $378.5K in salary.
Rankings
In 2018, Michael J. Tomsicek's compensation ranked 7,970th out of 14,244 executives tracked by ExecPay. In other words, Tomsicek earned more than 44.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 7,970 | 44th |
Manufacturing | 3,132 | 46th |
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 396 | 53rd |
Surgical, Medical, And Dental Instruments And Supplies | 228 | 58th |
Surgical and Medical Instruments and Apparatus | 141 | 60th |
Tomsicek's colleagues
We found five more compensation records of executives who worked with Michael J. Tomsicek at ABIOMED in 2018.
2018
Michael Minogue
ABIOMED
Chief Executive Officer
2018
David Weber
ABIOMED
Chief Operating Officer
2018
Michael Howley
ABIOMED
Vice President and General Manager, Global Sales
2018
William Bolt
ABIOMED
Senior Vice President, Global Quality, Regulatory and Clinical Operations
2018
Ian McLeod
ABIOMED
Chief Financial Officer
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019
ABIOMED CEO Michael Minogue's 2018 pay slips 16% to $10M
June 22, 2018